FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090927803> ?p ?o ?g. }

• W2090927803 endingPage "123" @default.
• W2090927803 startingPage "115" @default.
• W2090927803 abstract "A phase II study in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) was carried out to evaluate the clinical activity and toxicity of the chemotherapeutic combination of gemcitabine+vinorelbine (GEM/VNR). Forty-five patients (40 male, 5 female) with a median age of 67 years (range 37-73) and a median ECOG performance status of 1 (range 0-2) were enrolled into the trial. Twenty patients had stage IIIB (two positive supraclavicular nodes and 20 cytologically positive pleural effusion), and 25 had stage IV NSCLC. GEM 1000 mg/m(2) diluted in 250 cc(3) of normal saline was administered iv on days 1, 8, and 15, while VNR was given 30 mg/m(2) on days 1 and 8 every 4 weeks. The median number of courses/patient was 4 (range 3-7). According to an intent-to-treat analysis 2 (4%) patients had a complete response and 16 (36%; 95% CL 22-52%) had a partial response for an overall response rate of 40% (95% CL 26-56%). Twelve (27%) patients had stable disease and 15 (33%) were considered as treatment failures. Median overall survival of the whole series was 8+ months with 33% of patients alive at 1 year. Toxicity was generally mild. WHO grade 3-4 neutropenia was recorded in 22% of cases, grade 1-3 liver toxicity in 6% of patients and neutropenia-unrelated fever in 9%. This multicentre phase II study suggests that the GEM/VNR combination regimen is an active and well tolerated regimen in patients with stage IIIB/IV NSCLC. Larger studies comparing cisplatin-based regimens to new schedules without cisplatin are warranted." @default.
• W2090927803 created "2016-06-24" @default.
• W2090927803 creator A5003981479 @default.
• W2090927803 creator A5007487112 @default.
• W2090927803 creator A5011984492 @default.
• W2090927803 creator A5013748999 @default.
• W2090927803 creator A5025440569 @default.
• W2090927803 creator A5025969713 @default.
• W2090927803 creator A5029225725 @default.
• W2090927803 creator A5034325511 @default.
• W2090927803 creator A5036592189 @default.
• W2090927803 creator A5039439208 @default.
• W2090927803 creator A5044926112 @default.
• W2090927803 creator A5048720703 @default.
• W2090927803 creator A5073106835 @default.
• W2090927803 creator A5076245686 @default.
• W2090927803 creator A5077077042 @default.
• W2090927803 creator A5078561497 @default.
• W2090927803 date "2001-10-01" @default.
• W2090927803 modified "2023-10-16" @default.
• W2090927803 title "Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial" @default.
• W2090927803 cites W1579641819 @default.
• W2090927803 cites W1585991298 @default.
• W2090927803 cites W1788009048 @default.
• W2090927803 cites W1837121308 @default.
• W2090927803 cites W1848316250 @default.
• W2090927803 cites W1857358013 @default.
• W2090927803 cites W1858072261 @default.
• W2090927803 cites W1938837918 @default.
• W2090927803 cites W1942409573 @default.
• W2090927803 cites W1964842293 @default.
• W2090927803 cites W1979300931 @default.
• W2090927803 cites W1981343121 @default.
• W2090927803 cites W2001996041 @default.
• W2090927803 cites W2016263166 @default.
• W2090927803 cites W2059308557 @default.
• W2090927803 cites W2118512375 @default.
• W2090927803 cites W2129793485 @default.
• W2090927803 cites W2133972163 @default.
• W2090927803 cites W2153599729 @default.
• W2090927803 cites W2157784057 @default.
• W2090927803 cites W2167805334 @default.
• W2090927803 cites W2227314491 @default.
• W2090927803 cites W2254376071 @default.
• W2090927803 cites W2262092684 @default.
• W2090927803 cites W2266565546 @default.
• W2090927803 cites W2443193704 @default.
• W2090927803 cites W2462155706 @default.
• W2090927803 cites W2469194347 @default.
• W2090927803 cites W2504684570 @default.
• W2090927803 doi "https://doi.org/10.1016/s0169-5002(01)00206-9" @default.
• W2090927803 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11557121" @default.
• W2090927803 hasPublicationYear "2001" @default.
• W2090927803 type Work @default.
• W2090927803 sameAs 2090927803 @default.
• W2090927803 citedByCount "17" @default.
• W2090927803 countsByYear W20909278032013 @default.
• W2090927803 crossrefType "journal-article" @default.
• W2090927803 hasAuthorship W2090927803A5003981479 @default.
• W2090927803 hasAuthorship W2090927803A5007487112 @default.
• W2090927803 hasAuthorship W2090927803A5011984492 @default.
• W2090927803 hasAuthorship W2090927803A5013748999 @default.
• W2090927803 hasAuthorship W2090927803A5025440569 @default.
• W2090927803 hasAuthorship W2090927803A5025969713 @default.
• W2090927803 hasAuthorship W2090927803A5029225725 @default.
• W2090927803 hasAuthorship W2090927803A5034325511 @default.
• W2090927803 hasAuthorship W2090927803A5036592189 @default.
• W2090927803 hasAuthorship W2090927803A5039439208 @default.
• W2090927803 hasAuthorship W2090927803A5044926112 @default.
• W2090927803 hasAuthorship W2090927803A5048720703 @default.
• W2090927803 hasAuthorship W2090927803A5073106835 @default.
• W2090927803 hasAuthorship W2090927803A5076245686 @default.
• W2090927803 hasAuthorship W2090927803A5077077042 @default.
• W2090927803 hasAuthorship W2090927803A5078561497 @default.
• W2090927803 hasConcept C126322002 @default.
• W2090927803 hasConcept C141071460 @default.
• W2090927803 hasConcept C146357865 @default.
• W2090927803 hasConcept C151730666 @default.
• W2090927803 hasConcept C2776256026 @default.
• W2090927803 hasConcept C2776694085 @default.
• W2090927803 hasConcept C2776907518 @default.
• W2090927803 hasConcept C2777063308 @default.
• W2090927803 hasConcept C2778239845 @default.
• W2090927803 hasConcept C2779634585 @default.
• W2090927803 hasConcept C2780258809 @default.
• W2090927803 hasConcept C2780350996 @default.
• W2090927803 hasConcept C29730261 @default.
• W2090927803 hasConcept C31760486 @default.
• W2090927803 hasConcept C71924100 @default.
• W2090927803 hasConcept C86803240 @default.
• W2090927803 hasConcept C90924648 @default.
• W2090927803 hasConceptScore W2090927803C126322002 @default.
• W2090927803 hasConceptScore W2090927803C141071460 @default.
• W2090927803 hasConceptScore W2090927803C146357865 @default.
• W2090927803 hasConceptScore W2090927803C151730666 @default.
• W2090927803 hasConceptScore W2090927803C2776256026 @default.
• W2090927803 hasConceptScore W2090927803C2776694085 @default.
• W2090927803 hasConceptScore W2090927803C2776907518 @default.

• next